TD Private Client Wealth LLC Purchases 11,965 Shares of DexCom, Inc. $DXCM

TD Private Client Wealth LLC raised its holdings in DexCom, Inc. (NASDAQ:DXCM) by 3,715.8% in the 3rd quarter, HoldingsChannel reports. The firm owned 12,287 shares of the medical device company’s stock after purchasing an additional 11,965 shares during the quarter. TD Private Client Wealth LLC’s holdings in DexCom were worth $827,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. raised its holdings in DexCom by 1.8% during the 2nd quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after purchasing an additional 866,506 shares during the last quarter. Jennison Associates LLC lifted its holdings in DexCom by 9.4% during the second quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after acquiring an additional 994,300 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of DexCom by 3.4% during the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in DexCom by 106.8% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after purchasing an additional 3,410,858 shares in the last quarter. Finally, Norges Bank acquired a new stake in shares of DexCom during the second quarter worth $453,279,000. 97.75% of the stock is owned by institutional investors.

Insider Activity

In related news, COO Jacob Steven Leach acquired 18,200 shares of the company’s stock in a transaction on Monday, November 10th. The shares were acquired at an average cost of $55.04 per share, for a total transaction of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares in the company, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Richard Alexander Collins sold 2,906 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $59.05, for a total value of $171,599.30. Following the completion of the transaction, the director owned 35,088 shares in the company, valued at $2,071,946.40. The trade was a 7.65% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 7,866 shares of company stock worth $448,177 over the last quarter. 0.32% of the stock is currently owned by corporate insiders.

DexCom Stock Down 0.7%

Shares of NASDAQ DXCM opened at $69.24 on Friday. The firm has a market cap of $27.00 billion, a PE ratio of 38.47, a price-to-earnings-growth ratio of 1.26 and a beta of 1.48. The company has a 50 day simple moving average of $64.74 and a 200 day simple moving average of $71.76. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.56 and a quick ratio of 1.38. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. DexCom had a net margin of 15.96% and a return on equity of 30.65%. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.18 billion. During the same quarter in the prior year, the firm posted $0.45 EPS. The company’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, research analysts forecast that DexCom, Inc. will post 2.03 EPS for the current year.

Analysts Set New Price Targets

A number of analysts recently issued reports on DXCM shares. Barclays downgraded DexCom from an “equal weight” rating to an “underweight” rating and lowered their target price for the company from $80.00 to $71.00 in a research report on Monday. Piper Sandler set a $75.00 price objective on shares of DexCom and gave the company a “buy” rating in a report on Friday, October 31st. Argus lowered their target price on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Robert W. Baird set a $82.00 price target on DexCom in a research note on Friday, October 31st. Finally, Mizuho increased their target price on shares of DexCom from $75.00 to $78.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Two analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, four have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $86.30.

DexCom Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.